Objective To analyze the inhibitive effect of Keerkang Oral Liquid on adenovirus (ADV3) , parainfluenza virus (HVJ) , respiratory syncytial virus (RSV) , and herpes simplex virus 1 (HSV-1) , herpes simplex virus 2 ( HSV-2 ) in cell culture. Methods Sensitive cell culture was adopted, and chick embryo kidney (CEK) cells and bit hamster kidney (BHK) cells were used to infect homologous virus. Keerkang Oral Liquid was given after 2 hours, then cytopathie phenomenon (CPE) was observed. Results When the amounts of infected virus are less than or equal to 100TCID50, the group which was given Keerkang Oral Liquid showed CPE, while the virus control group showed 25%～75% CPE. Besideds Keerkang Oral Liquid showed inhibitive effect on maximum non-venom concentration (TD0) , medium effective concentration (IC50), minimum valid concentration (MTC) and therapeutic index (TI) ofADV3, HVJ, RSV, BSV-1, and HSV-2 by 0.5, 0.25, 0A25-0.0625 ml/ml and 4.8 respectively. Conclusion Keerkang Oral Liquid has obvious inhibitive effects on ADV3, HVJ,RSV and HSV-1, HSV-2 in cell culture, which provides experimental basis for treating ADV3, HVJ, RSV and HSV-1, and HSV-2.

Objective To analyze the effect of Kecrkang oral Liquid on extracorporeal bacteriostasis. Methods Tube dilution method was adopted to test the effect of different concentrations of Keerkang oral liquid on bacillus coli, klebsiella pneumoniae, bacillus aeruginosus, staphylococcus aureus, staphylococcus epidermidis, β-Streptococcus hemolyticus, streptococcus pneumoniae, haemophilus influenzae and candida albicans. Results Keerkang Oral Liquid has obvious inhibited effects to all the bacteria that mentioned above. Conclusion Keerkang Oral Liquid has obvious extracorporeal bacteriostasis and resistance to fungi.

Objective To evaluate cardiac involvement in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) using echocardiography combined with electrocardiography. Methods A retrospective analysis was performed on the detailed medical records of AAV patients treated in Jining First People’s Hospital between January 2020 and December 2024. Eighty patients were enrolled in the AAV group, and the risk of heart disease was compared between the AAV group and a control group with 80 subjects matched for age, sex, and cardiovascular disease risk factors. Results Electrocardiographic abnormalities were observed in 78.75% of patients in the AAV group, while significant electrocardiographic abnormalities only occurred in symptomatic patients in the control group. There were no differences in left atrial enlargement or interventricular septal thickening between the AAV group and the control group. The overall left ventricular systolic function in the AAV group was lower than that in the control group (8.75% vs. 0). The incidence of reduced diastolic function in the AAV group was significantly higher than that in the control group (37.5% vs. 15%). The incidence rates of tricuspid regurgitation, mitral regurgitation, aortic regurgitation, and pericardial effusion in the AAV group were significantly higher than those in the control group. Pericardial thickening, aortic stenosis, pulmonary hypertension, and rare periaortic granulomas were found in the AAV group, but not in the control group. Conclusion Echocardiography and electrocardiography are important examination methods for evaluating cardiac involvement in AAV. These methods have key roles in disease screening, diagnosis and treatment, follow-up, and prognosis judgment.